NASDAQ:NKTR - Nektar Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $20.11 -1.30 (-6.07 %) (As of 02/27/2020 11:02 AM ET) Add Compare Today's Range$19.78Now: $20.11▼$20.7450-Day Range$19.77MA: $22.67▼$27.9652-Week Range$15.64Now: $20.11▼$41.74Volume24,895 shsAverage Volume1.45 million shsMarket Capitalization$3.54 billionP/E RatioN/ADividend YieldN/ABeta2.62 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:NKTR Previous Symbol CUSIP64026810 CIK906709 Webhttp://www.nektar.com/ Phone415-482-5300Debt Debt-to-Equity Ratio0.26 Current Ratio12.60 Quick Ratio12.49Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.19 billion Price / Sales2.96 Cash Flow$3.63 per share Price / Cash Flow5.54 Book Value$9.92 per share Price / Book2.03Profitability EPS (Most Recent Fiscal Year)$3.78 Net Income$681.31 million Net Margins-352.83% Return on Equity-26.60% Return on Assets-20.01%Miscellaneous Employees618 Outstanding Shares175,920,000Market Cap$3.54 billion Next Earnings Date5/6/2020 (Estimated) OptionableOptionable Receive NKTR News and Ratings via Email Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NKTR Rates by TradingView Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions What is Nektar Therapeutics' stock symbol? Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR." How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) posted its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.17. The biopharmaceutical company earned $29.22 million during the quarter, compared to analyst estimates of $26.42 million. Nektar Therapeutics had a negative return on equity of 26.60% and a negative net margin of 352.83%. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.56) earnings per share. View Nektar Therapeutics' Earnings History. When is Nektar Therapeutics' next earnings date? Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Nektar Therapeutics. What price target have analysts set for NKTR? 14 equities research analysts have issued 12-month price targets for Nektar Therapeutics' stock. Their forecasts range from $16.00 to $41.00. On average, they expect Nektar Therapeutics' share price to reach $30.54 in the next year. This suggests a possible upside of 53.1% from the stock's current price. View Analyst Price Targets for Nektar Therapeutics. What is the consensus analysts' recommendation for Nektar Therapeutics? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 sell rating, 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nektar Therapeutics. What are Wall Street analysts saying about Nektar Therapeutics stock? Here are some recent quotes from research analysts about Nektar Therapeutics stock: 1. According to Zacks Investment Research, "Nektar has a promising pipeline with several regulatory updates/data-readouts lined up for the next several quarters. Moreover, regular partnerships have enhanced the company’s financial position. The blockbuster collaboration deal with Bristol-Myers for NKTR-214 significantly boosted Nektar’s cash resources. It also has encouraging co-development deals with other pharma companies. The deals boost revenues and reduce expenses by sharing research costs. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company’s results in the future. Shares of the company have underperformed the industry in the past year." (1/13/2020) 2. HC Wainwright analysts commented, "Our new 12-month, $24, vs. our prior $47 target on shares of Nektar is based on a 12-year DCF-driven, sum-of-the-parts analysis. Our DCF is driven by beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027." (8/13/2019) 3. William Blair analysts commented, "We traveled with LeMaitre management last week as the company met with Barrington clients in Richmond, VA. This marked the second time in a month that we have spent time on the road with members of this management team and the messaging remains consistent and long-term bullish despite some short-term challenges." (6/14/2019) 4. Mizuho analysts commented, "We expect these events to be important drivers for NKTR shares as we continue to believe that a majority of the company’s value lies in NKTR-214." (3/1/2019) Has Nektar Therapeutics been receiving favorable news coverage? Media coverage about NKTR stock has trended negative this week, according to InfoTrie. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nektar Therapeutics earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Nektar Therapeutics. Who are some of Nektar Therapeutics' key competitors? Some companies that are related to Nektar Therapeutics include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Hawkins (HWKN), Incyte (INCY), Gilead Sciences (GILD), Netflix (NFLX), Advanced Micro Devices (AMD), Intel (INTC) and AT&T (T). Who are Nektar Therapeutics' key executives? Nektar Therapeutics' management team includes the folowing people: Mr. Howard W. Robin, CEO, Pres & Director (Age 66)Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 47)Mr. John Nicholson, Sr. VP & COO (Age 67)Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. & Chief Technical Operations Officer (Age 65)Dr. Stephen K. Doberstein, Chief R&D Officer (Age 60) Who are Nektar Therapeutics' major shareholders? Nektar Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (8.49%), State Street Corp (2.59%), Maverick Capital Ltd. (1.84%), First Trust Advisors LP (1.69%), Geode Capital Management LLC (1.16%) and Goldman Sachs Group Inc. (1.11%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics. Which institutional investors are selling Nektar Therapeutics stock? NKTR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Geode Capital Management LLC, Janus Henderson Group PLC, Charles Schwab Investment Management Inc., UBS Asset Management Americas Inc., Swiss National Bank, Retirement Systems of Alabama and Bank of America Corp DE. Company insiders that have sold Nektar Therapeutics company stock in the last year include Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics. Which institutional investors are buying Nektar Therapeutics stock? NKTR stock was bought by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., FMR LLC, Goldman Sachs Group Inc., Principal Financial Group Inc., KBC Group NV, Bank of New York Mellon Corp, First Trust Advisors LP and American International Group Inc.. View Insider Buying and Selling for Nektar Therapeutics. How do I buy shares of Nektar Therapeutics? Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Nektar Therapeutics' stock price today? One share of NKTR stock can currently be purchased for approximately $19.95. How big of a company is Nektar Therapeutics? Nektar Therapeutics has a market capitalization of $3.51 billion and generates $1.19 billion in revenue each year. The biopharmaceutical company earns $681.31 million in net income (profit) each year or $3.78 on an earnings per share basis. Nektar Therapeutics employs 618 workers across the globe.View Additional Information About Nektar Therapeutics. What is Nektar Therapeutics' official website? The official website for Nektar Therapeutics is http://www.nektar.com/. How can I contact Nektar Therapeutics? Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected] MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 597 (Vote Outperform)Underperform Votes: 381 (Vote Underperform)Total Votes: 978MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/27/2020 by MarketBeat.com StaffFeatured Article: What is a dividend reinvestment plan?
